Cellectis gets US go-ahead to test ‘off-the-shelf’ cell therapy – Reuters

Cellectis has won U.S. regulatory approval to run an early clinical trial using its gene edited cell therapy product UCART123 for blood cancers, boosting the French biotech firm's ambitions in the hot area of cancer research.

Following approval from the Food and Drug Administration, Phase I clinical trials will start in the first half of this year, the company said on Monday.

It marks the first time that U.S. regulators have approved clinical testing of an allogeneic, or "off-the-shelf", gene-edited CAR T cell treatment.

The idea of genetically altering immune cells called T cells so that they can attack cancers more effectively has attracted interest from a range of drugmakers.

But while rivals such as Novartis, Juno and Kite have treatments that use modified T cells extracted from individual patients, Cellectis products are derived from healthy donors and aim to be universal.

Its first such "off-the-shelf" cell therapy UCART19, which is being developed with Servier and Pfizer, is now being tested in Phase I trials in Britain for acute lymphoblastic leukaemia and chronic lymphocytic leukaemia.

It has already rescued two babies treated at London's Great Ormond Street Hospital from previously incurable cancer.

UCART123, which is still wholly owned by Cellectis, is designed to help patients with acute myeloid leukaemia and blastic plasmacytoid dendritic cell neoplasm.

(Reporting by Ben Hirschler; Editing by Ruth Pitchford)

(Reuters Health) - Young people may be at risk for HIV infection, but very few get tested, partly because it can be difficult to access testing, researchers say.

(Reuters Health) - One in four teens who use electronic cigarettes have tried dripping liquid nicotine directly onto the heating coils on the devices to get thicker clouds of vapor, a new study suggests.

TOKYO Japan Tobacco Inc said it was still confident about the prospect of its Ploom Tech tobacco-based electronic cigarettes, the launch of which has been delayed due to supply problems, and raised its dividend despite forecasting a lower annual profit.

Here is the original post:
Cellectis gets US go-ahead to test 'off-the-shelf' cell therapy - Reuters